RESUMEN
Aneurysmal subarachnoid hemorrhage (SAH) can lead to devastating outcomes including vasospasm, cognitive decline, and even death. Currently, treatment options are limited for this potentially life threatening injury. Recent evidence suggests that neuroinflammation plays a critical role in injury expansion and brain damage. Red blood cell breakdown products can lead to the release of inflammatory cytokines that trigger vasospasm and tissue injury. Preclinical models have been used successfully to improve understanding about neuroinflammation following aneurysmal rupture. The focus of this review is to provide an overview of how neuroinflammation relates to secondary outcomes such as vasospasm after aneurysmal rupture and to critically discuss pharmaceutical agents that warrant further investigation for the treatment of subarachnoid hemorrhage. We provide a concise overview of the neuroinflammatory pathways that are upregulated following aneurysmal rupture and how these pathways correlate to long-term outcomes. Treatment of aneurysm rupture is limited and few pharmaceutical drugs are available. Through improved understanding of biochemical mechanisms of injury, novel treatment solutions are being developed that target neuroinflammation. In the final sections of this review, we highlight a few of these novel treatment approaches and emphasize why targeting neuroinflammation following aneurysmal subarachnoid hemorrhage may improve patient care. We encourage ongoing research into the pathophysiology of aneurysmal subarachnoid hemorrhage, especially in regards to neuroinflammatory cascades and the translation to randomized clinical trials.
Asunto(s)
Encéfalo/patología , Inflamación/complicaciones , Hemorragia Subaracnoidea/complicaciones , Hemorragia Subaracnoidea/patología , Animales , Encéfalo/irrigación sanguínea , Encéfalo/inmunología , Citocinas/análisis , Citocinas/inmunología , Humanos , Inflamación/inmunología , Inflamación/patología , Péptido Hidrolasas/análisis , Péptido Hidrolasas/inmunología , Hemorragia Subaracnoidea/inmunología , Hemorragia Subaracnoidea/terapia , VasoconstricciónRESUMEN
BACKGROUND: Wound complications, including surgical site infections (SSIs) and wound dehiscence, are among the most common complications following spine surgery often leading to readmission. The authors sought to identify preoperative characteristics predictive of wound complications after spine surgery. METHODS: The American College of Surgeons National Surgical Quality Improvement Program database for years 2012-2014 was reviewed for patients undergoing spine surgery, defined by the Current Procedural Terminology codes. Forty-four preoperative and surgical characteristics were analyzed for associations with wound complications. RESULTS: Of the 99,152 patients included in this study, 2.2% experienced at least one wound complication (superficial SSI: 0.9%, deep SSI: 0.8%, organ space SSI: 0.4%, and dehiscence: 0.3%). Multivariate binary logistic regression testing found 10 preoperative characteristics associated with wound complications: body mass index ≥30, smoker, female, chronic steroid use, hematocrit <38%, infected wound, inpatient status, emergency case, and operation time >3 hours. A risk score for each patient was created from the number of characteristics present. Receiver operating characteristic curves of the unweighted and weighted risk scores generated areas under the curve of 0.701 (95% CI: 0.690-0.713) and 0.715 (95% CI: 0.704-0.726), respectively. Patients with unweighted risk scores >7 were 25-fold more likely to develop a wound complication compared to patients with scores of 0. In addition, mortality rate, reoperation rate, and total length of stay each increased nearly 10-fold with increasing risk score. CONCLUSION: This study introduces a novel risk score for the development of wound dehiscence and SSIs in patients undergoing spine surgery, using new risk factors identified here.
RESUMEN
OBJECTIVE: To identify clinical factors predictive of patients returning to the operating room (OR) for hemorrhage after craniotomy. METHODS: A national surgical quality database (American College of Surgeons National Surgical Quality Improvement Project) was reviewed for patients undergoing craniotomy based on Current Procedural Terminology (CPT) code. CPT codes were also used to identify patients returning to the OR for hemorrhage. RESULTS: Of 5520 patients who underwent craniotomy in 2012, 81 (1.5%) had a reoperation for hematoma evacuation. Preoperative and intraoperative factors associated with reoperation for hemorrhage included preexisting hypertension, bleeding disorder, and primary craniotomy for hematoma evacuation. Postoperative factors included ventilator dependence >48 hours, unplanned reintubation, and blood transfusion during or after the index operation. A risk score based on these factors was predictive of reoperation for hemorrhage with a receiver operating characteristic area under the curve of 0.767. Restricting the score to preoperative factors was still predictive of reoperation (area under the curve = 0.683). CONCLUSIONS: Reoperation for evacuation of hematoma is influenced by several clinical factors. A risk score based on these factors is predictive of return to the OR and may be used to identify patients at risk.
Asunto(s)
Craneotomía/efectos adversos , Hemorragias Intracraneales/cirugía , Procedimientos Neuroquirúrgicos/estadística & datos numéricos , Complicaciones Posoperatorias/etiología , Hemorragia Posoperatoria/cirugía , Reoperación/estadística & datos numéricos , Estudios de Cohortes , Bases de Datos Factuales , Femenino , Hematoma/cirugía , Humanos , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/epidemiología , Valor Predictivo de las Pruebas , Cobertura de Afecciones Preexistentes , Curva ROC , Medición de Riesgo , Factores de Riesgo , Segunda CirugíaRESUMEN
Calcium pyrophosphate dihydrate deposition disease (CPDD, tophaceous pseudogout) is a rare crystal arthropathy characterized by calcium pyrophosphate crystal deposition in joint spaces, episodes of synovitis, and radiological features of chondrocalcinosis. We present a case of 61-year-old woman who presented with left temporomandibular joint (TMJ) pain, difficulty chewing, left facial numbness, left-sided hearing loss, and left TMJ swelling. Imaging of the temporal fossa revealed a large mass emanating from the temporal bone at the TMJ, extending into the greater wing of the sphenoid and involving the mastoid bone and air cells posteriorly. Fine needle aspiration demonstrated polarizable crystals with giant cells. Intraoperatively, the TMJ was completely eroded by the mass. Final pathology was consistent with tophaceous pseudogout. CPDD has rarely been reported involving the skull base. None of the cases originally described by McCarty had TMJ pseudogout. Symptoms are generally pain, swelling, and hearing loss. Management is nearly always surgical with many patients achieving symptomatic relief with resection. CPDD is associated with many medical problems (including renal failure, gout, and hyperparathyroidism), but our patient had none of these risk factors. This case demonstrates that CPDD can involve the skull base and is best treated with skull base surgical techniques.